/
RSS Feed
Peter Smith, Duke University Medical Center, Durham, NC
Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006
The drug pexelizumab, targeting inflammation, reduced the risk of death among patients about to have coronary artery by-pass grafting in the PRIMOCABG-II study. Peter Smith of Duke University told the ACC about his group’s findings.
[audio:https://www.audiomedica.com/podcasting/acc2006/peter_smith.mp3] Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006
The drug pexelizumab, targeting inflammation, reduced the risk of death among patients about to have coronary artery by-pass grafting in the PRIMOCABG-II study. Peter Smith of Duke University told the ACC about his group’s findings.
